New Choices to Help Improve mAbs Downstream Manufacturing Efficiency: Introducing the J.T.Baker® BAKERBOND® PROchievA™ Recombinant Protein A Resin

Sponsored by Avantor

October 7, 2020

An integrated mAbs downstream purification process featuring Avantor J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A chromatography columns and resins can enable significant throughput improvement while removing critical impurities.

Protein A chromatography is a proven downstream purification step in manufacturing monoclonal antibodies (mAbs), but there remains a need to reduce the total purification costs while improving purity and yield.

Avantor J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A chromatography columns and resins are optimized to deliver top performance in downstream processing with demonstrated, higher protein purity levels in more complex biopharmaceuticals such as Fc fusion proteins and bispecific antibodies.

Through use of pre-absorption filtration technology in combination with the J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A resin that possess high dynamic binding capacities of greater than 60 g/L, antibodies with increased purity can be obtained while reducing overall process time. Processes may be refined even further by using select additives during process chromatography, enhancing target antibody selectivity as a result by removing host cell protein impurities and aggregates.

Watch a recent presentation to learn how an integrated downstream purification process using the J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A resin and other J.T.Baker® BAKERBOND® resins can enable significant throughput improvement in mAb manufacturing while removing critical impurities.